NCT03695471 - Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

June 21, 2023

Study Completion Date

October 8, 2024

Conditions

Mycosis FungoidesSezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8

Interventions

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville